Northland Capmk Issues Positive Outlook for BLFS Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Research analysts at Northland Capmk raised their Q3 2025 earnings per share estimates for shares of BioLife Solutions in a research note issued to investors on Monday, March 3rd. Northland Capmk analyst C. Byrnes now anticipates that the medical equipment provider will post earnings per share of $0.00 for the quarter, up from their previous estimate of ($0.01). The consensus estimate for BioLife Solutions' current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions' Q4 2025 earnings at $0.01 EPS.

BLFS has been the topic of several other research reports. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Wednesday, January 8th. TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Benchmark restated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, HC Wainwright boosted their price objective on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.86.

Remove Ads

BioLife Solutions Price Performance

Shares of BLFS traded down $0.97 during midday trading on Wednesday, hitting $25.83. The company's stock had a trading volume of 608,317 shares, compared to its average volume of 283,669. BioLife Solutions has a one year low of $14.84 and a one year high of $29.55. The company's fifty day simple moving average is $26.65 and its two-hundred day simple moving average is $25.49. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -24.37 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analysts' expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the firm earned ($0.21) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new stake in BioLife Solutions in the fourth quarter worth $26,000. Mark Sheptoff Financial Planning LLC purchased a new stake in BioLife Solutions in the third quarter worth $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in BioLife Solutions during the fourth quarter valued at $31,000. Quest Partners LLC purchased a new position in BioLife Solutions during the third quarter valued at $57,000. Finally, 1620 Investment Advisors Inc. lifted its position in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares during the period. Institutional investors own 93.24% of the company's stock.

Insider Buying and Selling

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the transaction, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,978 shares of company stock worth $322,724. Corporate insiders own 2.20% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.